Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California.
Gilead Sciences, Inc. isounded in 1987 by Michael L. Riordan, the company focuses on the discovery, development, and commercialization of innovative medicines, particularly antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19.
HIV/AIDS: Gilead has developed several treatments that have significantly improved the lives of millions of people living with HIV/AIDS.
Liver Diseases: The company has made significant advancements in the treatment of liver diseases, including hepatitis B and C.
Cardiovascular and Respiratory Conditions: Gilead also focuses on serious cardiovascular and respiratory conditions, developing therapeutics to improve patient outcomes.
Gilead markets its products through commercial teams, third-party distributors, and corporate partners. It has a diverse portfolio of marketed drugs and a robust pipeline of drugs in development. Some of its well-known products include AmBisome, Atripla, and Truvada.
Gilead is a publicly traded company and a member of the NASDAQ Biotechnology Index and the S&P 500. As of June 21, 2024, its stock price was $70.67. The company has a significant global presence, with subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East, and Africa.
In recent years, Gilead has expanded its research and development efforts through acquisitions and collaborations. For example, in 2024, it entered into agreements to develop therapies for triple-negative breast cancer and adenocarcinoma and expanded its collaboration with Nurix Therapeutics.
Gilead Sciences continues to be a leader in the biopharmaceutical industry, driven by its commitment to innovation and improving patient care worldwide.